In 2017, cancer might finally become number one. It would be an upset victory, given that heart disease has killed more people in the US every year for nearly a century. But it wouldn’t exactly be a surprise: As deaths from heart disease and stroke have dwindled, cancer has held strong, steadily narrowing the gap. If it doesn’t win out this year, it will soon.
[…] The quest for the best of these “neoantigens” is underway in many groups; a project from Sean Parker’s new cancer immunotherapy institute, announced in early December, is a collaboration/competition between some 30 research groups and companies to look for these targets in established cancers. Their first rough draft list is expected in the spring.